A British Thoracic Oncology Group Phase III Trial of Gemcitabine Plus Cisplatin at 80mg/m Versus Gemcitabine Plus Carboplatin At 50 mg/m Versus Gemcitabine Plus Carboplatin AUC 6 in Stage IIIB/IV Non-Small Cell Lung Cancer (NSCLC).

Trial Profile

A British Thoracic Oncology Group Phase III Trial of Gemcitabine Plus Cisplatin at 80mg/m Versus Gemcitabine Plus Carboplatin At 50 mg/m Versus Gemcitabine Plus Carboplatin AUC 6 in Stage IIIB/IV Non-Small Cell Lung Cancer (NSCLC).

Completed
Phase of Trial: Phase III

Latest Information Update: 03 Aug 2017

At a glance

  • Drugs Gemcitabine (Primary) ; Carboplatin; Cisplatin
  • Indications Non-small cell lung cancer
  • Focus Registrational; Therapeutic Use
  • Most Recent Events

    • 03 Aug 2017 Primary endpoint (Length of survival, GC50 vs GCb6 and GC80) has not been met as per the results published in the European Journal of Cancer.
    • 03 Aug 2017 Primary endpoint (Length of survival, GCb6 vs GC80) has been met as per the results published in the European Journal of Cancer.
    • 03 Aug 2017 Primary endpoint (Length of survival) has not been met as per the results published in the European Journal of Cancer.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top